Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction

International Journal of Cardiology

Volumn 195, Issue , 2015, Pages 104-110

  Serebruany, Victor L ^a   Cherepanov, Vasily ^a   Tomek, Ales ^b   Kim, Moo Hyun ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Dong A University   (South Korea)

Author keywords

Antithrombotics; Clinical trials; Clopidogrel; Mortality; Prasugrel; ST elevated myocardial infarction; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; HEPARIN; HIRULOG; PRASUGREL; TICAGRELOR; TIROFIBAN; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOSIS; TREND STUDY; ANALOGS AND DERIVATIVES; ELECTROCARDIOGRAPHY; MORTALITY; MYOCARDIAL INFARCTION; PROCEDURES; SURVIVAL;

ADENOSINE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TICLOPIDINE;

EID: 84937565684     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.05.062     Document Type: Article

References (26)

1. Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, R. Peto, R. Collins, L.S. Liu COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
2. V.L. Serebruany Comment: mortality benefit of no-load clopidogrel in COMMIT: not a surprise J. Cardiovasc. Pharmacol. Ther. 11 2006 99 100
3. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.J. Neumann, D. Ardissino, S. De Servi, S.A. Murphy, J. Riesmeyer, G. Weerakkody, C.M. Gibson, E.M. Antman TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 357 2007 2001 2015
4. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K.W. Mahaffey, B.M. Scirica, A. Skene, P.G. Steg, R.F. Storey, and R.A. Harrington Ticagrelor versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 361 2009 1045 1057
5. S. Palacio, R.G. Hart, L.A. Pearce, and O.R. Benavente Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials Stroke 43 2012 2157 2162
6. T.J. Helton, A.A. Bavry, D.J. Kumbhani, S. Duggal, H. Roukoz, and D.L. Bhatt Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Am. J. Cardiovasc. Drugs 7 2007 289 297
7. G. Montalescot, A.W. van 't Hof, F. Lapostolle, J. Silvain, J.F. Lassen, L. Bolognese, W.J. Cantor, A. Cequier, M. Chettibi, S.G. Goodman, C.J. Hammett, K. Huber, M. Janzon, B. Merkely, R.F. Storey, U. Zeymer, O. Stibbe, P. Ecollan, W.M. Heutz, E. Swahn, J.P. Collet, F.F. Willems, C. Baradat, M. Licour, A. Tsatsaris, E. Vicaut, C.W. Hamm ATLANTIC Investigators Prehospital ticagrelor in ST-segment elevation myocardial infarction N. Engl. J. Med. 371 2014 1016 1027
8. D.F. Stroup, J.A. Berlin, S.C. Morton, and I. Olkin Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 283 2000 2008 2012
9. A.L. Boyles, S.F. Harris, A.A. Rooney, and K.A. Thayer Forest Plot Viewer: a new graphing tool Epidemiology 22 2011 746 747
10. P.G. Steg, S. James, R.A. Harrington, D. Ardissino, R.C. Becker, C.P. Cannon, H. Emanuelsson, A. Finkelstein, S. Husted, H. Katus, J. Kilhamn, S. Olofsson, R.F. Storey, W.D. Weaver, L. Wallentin, and PLATO Study Group Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
11. G. Montalescot, S.D. Wiviott, E. Braunwald, S.A. Murphy, C.M. Gibson, C.H. McCabe, E.M. Antman TRITON-TIMI 38 investigators Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
12. A. Koshy, K. Balasubramaniam, A. Noman, and A.G. Zaman Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel Cardiovasc. Ther. 32 2014 1 6
13. R.A. Harrington, G.W. Stone, S. McNulty, H.D. White, A.M. Lincoff, C.M. Gibson, C.V. Pollack Jr., G. Montalescot, K.W. Mahaffey, N.S. Kleiman, S.G. Goodman, M. Amine, D.J. Angiolillo, R.C. Becker, D.P. Chew, W.J. French, F. Leisch, K.H. Parikh, S. Skerjanec, and D.L. Bhatt Platelet inhibition with cangrelor in patients undergoing PCI N. Engl. J. Med. 361 2009 2318 2329
14. S. Schulz, G. Richardt, K.L. Laugwitz, T. Morath, J. Neudecker, P. Hoppmann, R. Mehran, A.H. Gershlick, R. Tölg, K. Anette Fiedler, M. Abdel-Wahab, S. Kufner, S. Schneider, H. Schunkert, T. Ibrahim, J. Mehilli, A. Kastrati Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Investigators Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction Eur. Heart J. 35 2014 2285 2294
15. Y. Han BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin: a Randomised Controlled Trial (BRIGHT); ClinicalTrials.gov: NCT01696110 Presentation slides from TCT 2014
16. J.M. ten Berg, A.W. van't Hof, T. Dill, T. Heestermans, J.W. van Werkum, A. Mosterd, G. van Houwelingen, P.C. Koopmans, P.R. Stella, E. Boersma, and C. Hamm On-TIME 2 Study Group. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome J. Am. Coll. Cardiol. 55 2010 2446 2455
17. U. Zeymer, A. van 't Hof, J. Adgey, L. Nibbe, P. Clemmensen, C. Cavallini, J. ten Berg, P. Coste, K. Huber, E.N. Deliargyris, J. Day, D. Bernstein, P. Goldstein, C. Hamm, and P.G. Steg Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial Eur. Heart J. 35 2014 2460 2467
18. A. Shahzad, I. Kemp, C. Mars, K. Wilson, C. Roome, R. Cooper, M. Andron, C. Appleby, M. Fisher, A. Khand, B. Kunadian, J.D. Mills, J.L. Morris, W.L. Morrison, S. Munir, N.D. Palmer, R.A. Perry, D.R. Ramsdale, P. Velavan, R.H. Stables HEAT-PPCI trial investigators Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial Lancet 384 9957 2014 1849 1858
19. G.W. Stone, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B.J. Gersh, S.J. Pocock, G. Dangas, S.C. Wong, A.J. Kirtane, H. Parise, R. Mehran HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N. Engl. J. Med. 358 2008 2218 2230
20. The FDA ticagrelor review of complete response Available for download at http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000MedR.pdf Assessed January 16, 2015
21. Food and Drug Administration Briefing document, February 3, 2009 meeting of FDA Cardiovascular and Renal Drugs Advisory Committee on Prasugrel Available for download at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm181185.pdf [Assessed January 16, 2015]
22. G.N. Levine, Y.H. Jeong, S. Goto, J.L. Anderson, Y. Huo, J.L. Mega, K. Taubert, and S.C. Smith Jr. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI Nat. Rev. Cardiol. 11 2014 597 606
23. V.L. Serebruany Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified Thromb. Haemost. 105 2011 752 759
24. J.L. Mega, E. Braunwald, S.A. Murphy, A.N. Plotnikov, P. Burton, R.G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, and C.M. Gibson Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51) J. Am. Coll. Cardiol. 61 2013 1853 1859
25. K.Y. Chen, S.W. Rha, Y.J. Li, K.L. Poddar, Z. Jin, Y. Minami, L. Wang, E.J. Kim, C.G. Park, H.S. Seo, D.J. Oh, M.H. Jeong, Y.K. Ahn, T.J. Hong, Y.J. Kim, S.H. Hur, I.W. Seong, J.K. Chae, M.C. Cho, J.H. Bae, D.H. Choi, Y.S. Jang, I.H. Chae, C.J. Kim, J.H. Yoon, W.S. Chung, K.B. Seung, S.J. Park Korea Acute Myocardial Infarction Registry Investigators Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention Circulation 119 2009 3207 3214
26. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. López-Sendón, G. Montalescot, P. Theroux, M.J. Claeys, F. Cools, K.A. Hill, A.M. Skene, C.H. McCabe, E. Braunwald CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N. Engl. J. Med. 352 2005 1179 1189